SCHEMBL3933238

SCHEMBL3933238

CCNCc1ccc(NC(=C2C(=O)Nc3cc(F)ccc32)c2ccc3c(c2)OCCO3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.43
RAB9A P51151 6/20 0.39
NPC1 O15118 5/20 0.39
MAPT P10636 4/20 0.39
MAPK1 P28482 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 3/20 0.39
STAT1 P42224 1/20 0.39
KMT2A Q03164 3/20 0.38
ALOX12 P18054 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
HPGD P15428 1/20 0.37
NAMPT P43490 1/20 0.36
LMNA P02545 3/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933227 1.00 MAOB (0.43) MAOBRAB9ANPC1MAPTMAPK1
SCHEMBL3939666 0.95 KMT2A (0.44) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5857584 0.95 KMT2A (0.44) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL3944362 0.89 MAPT (0.42) MAOBRAB9ANPC1MAPTMAPK1
SCHEMBL3944374 0.89 MAPT (0.42) MAOBRAB9ANPC1MAPTMAPK1
SCHEMBL5858365 0.89 BACE1 (0.36) RAB9AMAPTSMN1; SMN2ALDH1A1KMT2A
SCHEMBL3940679 0.89 BACE1 (0.36) RAB9AMAPTSMN1; SMN2ALDH1A1KMT2A
SCHEMBL3939762 0.88 VNN1 (0.42) MAOBRAB9ANPC1MAPTMAPK1
SCHEMBL3939757 0.88 VNN1 (0.42) MAOBRAB9ANPC1MAPTMAPK1
SCHEMBL3936040 0.87 MEN1 (0.41) RAB9ANPC1MAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP claimed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US claimed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US claimed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAOB 628/4885RAB9A 3709/4885NPC1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.